

David Burn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1272680/publications.pdf>

Version: 2024-02-01

241
papers

24,249
citations

6254

80
h-index

8866

145
g-index

244
all docs

244
docs citations

244
times ranked

21015
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	3.9	1,908
2	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	3.9	885
3	How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2013, 28, 668-670.	3.9	622
4	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608
5	Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. <i>Brain</i> , 2004, 127, 791-800.	7.6	544
6	<sc>EFNS</sc>/<sc>MDS</sc>â€<sc>ES</sc> recommendations for the diagnosis of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	3.3	460
7	Identifying prodromal Parkinson's disease: Preâ€Motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 617-626.	3.9	443
8	Parkinson's disease: The quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011, 26, 1022-1031.	3.9	349
9	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	6.2	333
10	The retina in Parkinson's disease. <i>Brain</i> , 2009, 132, 1128-1145.	7.6	327
11	Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2004, 61, 919.	4.5	312
12	Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. <i>Movement Disorders</i> , 2006, 21, 148-158.	3.9	312
13	New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. <i>Lancet, The</i> , 1997, 350, 903-907.	13.7	299
14	Healthâ€related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. <i>Movement Disorders</i> , 2014, 29, 195-202.	3.9	292
15	Summary of the recommendations of the <sc>EFNS</sc>/<sc>MDS</sc>â€<sc>ES</sc> review on therapeutic management of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	3.3	290
16	Tau and Î±â€synuclein in susceptibility to, and dementia in, Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 145-153.	5.3	256
17	Life with communication changes in Parkinsonâ€™s disease. <i>Age and Ageing</i> , 2006, 35, 235-239.	1.6	254
18	A phase 2 trial of the GSKâ€3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 470-478.	3.9	251

#	ARTICLE	IF	CITATIONS
19	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , 2014, 13, 676-685.	10.2	245
20	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	3.9	244
21	Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 326-345.	6.1	216
22	Prevalence and Severity of Gait Disorders in Alzheimer's and Non-Alzheimer's Dementias. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1681-1687.	2.6	214
23	Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. <i>Movement Disorders</i> , 2007, 22, 2398-2404.	3.9	214
24	Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). <i>Movement Disorders</i> , 2016, 31, 995-1003.	3.9	211
25	Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 229-237.	1.5	206
26	Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. <i>Annals of Neurology</i> , 2003, 54, 235-238.	5.3	204
27	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. <i>Human Molecular Genetics</i> , 2011, 20, 345-353.	2.9	202
28	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. <i>Brain</i> , 2005, 128, 1267-1276.	7.6	201
29	Hard to swallow: dysphagia in Parkinson's disease. <i>Age and Ageing</i> , 2006, 35, 614-618.	1.6	198
30	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [¹²³ I]FP-CIT SPECT. <i>Movement Disorders</i> , 2009, 24, 500-508.	3.9	195
31	The interplay of cholinergic function, attention, and falls in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2496-2503.	3.9	193
32	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	3.9	193
33	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2015, 138, 2974-2986.	7.6	188
34	Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. <i>Brain</i> , 2012, 135, 2779-2788.	7.6	187
35	Impaired attention predicts falling in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 110-115.	2.2	179
36	Mitochondrial DNA haplogroup cluster UK1T reduces the risk of PD. <i>Annals of Neurology</i> , 2005, 57, 564-567.	5.3	178

#	ARTICLE	IF	CITATIONS
37	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309.	3.3	170
38	Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype. <i>Movement Disorders</i> , 2015, 30, 359-367.	3.9	168
39	New evidence on the management of Lewy body dementia. <i>Lancet Neurology</i> , The, 2020, 19, 157-169.	10.2	167
40	The clinical approach to movement disorders. <i>Nature Reviews Neurology</i> , 2010, 6, 29-37.	10.1	166
41	Visual symptoms in Parkinson's disease and Parkinson's disease dementia. <i>Movement Disorders</i> , 2011, 26, 2387-2395.	3.9	164
42	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2012, 27, 1754-1762.	3.9	163
43	The expanding universe of disorders of the basal ganglia. <i>Lancet</i> , The, 2014, 384, 523-531.	13.7	155
44	Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 153-160.	1.2	153
45	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 826.	4.5	147
46	The nature of dual-task interference during gait in incident Parkinson's disease. <i>Neuroscience</i> , 2014, 265, 83-94.	2.3	147
47	Systematic Review and UK-Based Study of <i>PARK2</i> (parkin), <i>PINK1</i> , <i>PARK7</i> (<i>DJ-1</i>) and <i>LRRK2</i> in early-onset Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1522-1529.	3.9	141
48	Progressive supranuclear palsy: where are we now?. <i>Lancet Neurology</i> , The, 2002, 1, 359-369.	10.2	140
49	Ambulatory activity in incident Parkinson's: more than meets the eye?. <i>Journal of Neurology</i> , 2013, 260, 2964-2972.	3.6	140
50	SPECTRUM OF PARKINSON'S DISEASE, PARKINSON'S DEMENTIA, AND LEWY BODY DEMENTIA. <i>Neurologic Clinics</i> , 2000, 18, 865-883.	1.8	138
51	Regional cerebral blood flow in Parkinson's disease with and without dementia. <i>NeuroImage</i> , 2003, 20, 1309-1319.	4.2	136
52	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 47-53.	2.2	133
53	Gray and white matter imaging: α biomarker for cognitive impairment in early β Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 103-110.	3.9	129
54	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1518-1526.	3.9	128

#	ARTICLE	IF	CITATIONS
55	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2014, 137, 2743-2758.	7.6	127
56	Delayed gastric emptying in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 23-32.	3.9	124
57	Dementia with Lewy bodies. <i>Seminars in Clinical Neuropsychiatry</i> , 2003, 8, 46-57.	1.9	124
58	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 339-345.	10.2	118
59	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	3.9	117
60	Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 236-241.	3.9	116
61	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2483-2495.	3.9	115
62	Parkinson's disease motor subtypes and mood. <i>Movement Disorders</i> , 2012, 27, 379-386.	3.9	114
63	Executive dysfunction and attention contribute to gait interference in "off" state Parkinson's Disease. <i>Gait and Posture</i> , 2010, 31, 169-174.	1.4	112
64	Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1071-1075.	2.2	110
65	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	2.5	110
66	Progression of White Matter Hyperintensities in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia: A Comparison With Normal Aging. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 842-849.	1.2	108
67	Retinal thickness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 431-436.	2.2	107
68	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	3.9	106
69	Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 1000-1004.	5.3	106
70	Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction?. <i>Journal of Neurology</i> , 2011, 258, 566-572.	3.6	105
71	How do I sound to me? Perceived changes in communication in Parkinson's disease. <i>Clinical Rehabilitation</i> , 2008, 22, 14-22.	2.2	103
72	Mild cognitive impairment in Parkinson's disease. <i>Age and Ageing</i> , 2013, 42, 567-576.	1.6	103

#	ARTICLE	IF	CITATIONS
73	Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 172-180.	2.3	102
74	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 424-433.	3.9	101
75	Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. <i>Movement Disorders</i> , 2007, 22, 55-61.	3.9	100
76	Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?. <i>Movement Disorders</i> , 2016, 31, 937-946.	3.9	99
77	Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4-year study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 626-631.	2.7	97
78	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377.	9.0	94
79	MRI Study of Caudate Nucleus Volume in Parkinson's Disease with and without Dementia with Lewy Bodies and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 57-63.	1.5	88
80	Lower urinary tract symptoms in Parkinson's disease: Prevalence, aetiology and management. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 8-16.	2.2	88
81	Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naïve cohort. <i>Movement Disorders</i> , 2016, 31, 1829-1836.	3.9	87
82	Late-onset axial jerky dystonia due to the DYT1 deletion. <i>Movement Disorders</i> , 2002, 17, 196-198.	3.9	86
83	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. <i>Neuroscience Letters</i> , 2003, 341, 177-180.	2.1	81
84	Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?. <i>Movement Disorders</i> , 2013, 28, 425-438.	3.9	81
85	Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. <i>Journal of Parkinson's Disease</i> , 2013, 3, 1-11.	2.8	79
86	The association between retirement and age on physical activity in older adults. <i>Age and Ageing</i> , 2014, 43, 386-393.	1.6	76
87	The basal ganglia in perceptual timing: Timing performance in Multiple System Atrophy and Huntington's disease. <i>Neuropsychologia</i> , 2014, 52, 73-81.	1.6	74
88	Separating Parkinson's Disease From Normality. <i>Archives of Neurology</i> , 1994, 51, 237.	4.5	73
89	Cognition and Gait Show a Selective Pattern of Association Dominated by Phenotype in Incident Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 249.	3.4	73
90	Visual complaints and visual hallucinations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 318-322.	2.2	73

#	ARTICLE	IF	CITATIONS
91	Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 979-985.	3.3	73
92	Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues. <i>Movement Disorders</i> , 2011, 26, 430-435.	3.9	72
93	Visual exploration in Parkinson's disease and Parkinson's disease dementia. <i>Brain</i> , 2013, 136, 739-750.	7.6	72
94	The pattern of habitual sedentary behavior is different in advanced Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2114-2120.	3.9	71
95	Predicting the cost of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 804-812.	3.9	70
96	Pathological correlates of frontotemporal lobar degeneration in the elderly. <i>Acta Neuropathologica</i> , 2011, 121, 365-371.	7.7	70
97	Cholinergic systems in progressive supranuclear palsy. <i>Brain</i> , 2004, 128, 239-249.	7.6	69
98	Clinical, Genetic, and Radiological Features of Extrapyrimal Movement Disorders in Mitochondrial Disease. <i>JAMA Neurology</i> , 2016, 73, 668.	9.0	69
99	More Severe Functional Impairment in Dementia With Lewy Bodies Than Alzheimer Disease Is Related to Extrapyrimal Motor Dysfunction. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 582-588.	1.2	65
100	Tracking Parkinson's: Study Design and Baseline Patient Data. <i>Journal of Parkinson's Disease</i> , 2015, 5, 947-959.	2.8	64
101	The effects of cognitive reserve and lifestyle on cognition and dementia in Parkinson's disease—a longitudinal cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 13-23.	2.7	63
102	Fall in circulating mononuclear cell mitochondrial DNA content in human sepsis. <i>Intensive Care Medicine</i> , 2010, 36, 956-962.	8.2	62
103	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2014, 37, 9-16.	0.7	62
104	Accumulation of dipeptide repeat proteins predates that of <i>TDP-43</i> in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <i>C9ORF72</i> gene. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 601-612.	3.2	62
105	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. <i>Brain</i> , 2019, 142, 2828-2844.	7.6	62
106	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology</i> , The, 2021, 20, 107-116.	10.2	62
107	Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy. <i>Movement Disorders</i> , 2006, 21, 199-207.	3.9	61
108	Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 79-88.	1.8	60

#	ARTICLE	IF	CITATIONS
109	The relationship between real world ambulatory activity and falls in incident Parkinson's disease: Influence of classification scheme. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 236-242.	2.2	59
110	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1062-1066.	3.9	59
111	The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. <i>NeuroImage</i> , 2004, 23, 956-966.	4.2	58
112	Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1081-1086.	3.6	58
113	metabolic profiling of Parkinson's disease and mild cognitive impairment. <i>Movement Disorders</i> , 2017, 32, 927-932.	3.9	58
114	Distribution of cranial MRI abnormalities in patients with symptomatic and subclinical CADASIL. <i>British Journal of Radiology</i> , 2000, 73, 256-265.	2.2	57
115	Thinking positively about chronic illness: An exploration of optimism, illness perceptions and well-being in patients with Parkinson's disease. <i>British Journal of Health Psychology</i> , 2014, 19, 363-379.	3.5	57
116	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , 2012, 27, 312-315.	3.9	56
117	Short latency afferent inhibition: A biomarker for mild cognitive impairment in Parkinson's disease?. <i>Movement Disorders</i> , 2013, 28, 1285-1288.	3.9	56
118	3-D motion system ("data-gloves"): application for Parkinson's disease. <i>IEEE Transactions on Instrumentation and Measurement</i> , 2003, 52, 662-674.	4.7	55
119	The Role of Vitamin D in Disease Progression in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 669-675.	2.8	55
120	In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. <i>NeuroImage</i> , 2006, 33, 423-429.	4.2	54
121	Towards an EMG-Controlled Prosthetic Hand Using a 3-D Electromagnetic Positioning System. <i>IEEE Transactions on Instrumentation and Measurement</i> , 2007, 56, 178-186.	4.7	53
122	Rapid eye movement sleep behavior disorder in Parkinson's disease: Magnetic resonance imaging study. <i>Movement Disorders</i> , 2013, 28, 832-836.	3.9	52
123	Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 161-167.	1.5	51
124	Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. <i>Journal of Parkinson's Disease</i> , 2014, 4, 131-137.	2.8	50
125	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 63-68.	2.2	50
126	Cortical Lewy body disease and Parkinson's disease dementia. <i>Current Opinion in Neurology</i> , 2006, 19, 572-579.	3.6	49

#	ARTICLE	IF	CITATIONS
127	Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis. <i>Psychological Medicine</i> , 2016, 46, 657-667.	4.5	49
128	Neural correlates of attention and executive dysfunction in lewy body dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 1254-1270.	3.6	49
129	Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2017, 38, 1702-1715.	3.6	49
130	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 55, 78-90.	3.1	48
131	Frontotemporal Dementia in Elderly Individuals. <i>Archives of Neurology</i> , 2012, 69, 1052.	4.5	46
132	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 96-101.	2.2	46
133	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , 2020, 35, 601-611.	5.7	45
134	One Year Follow-Up of Parkinsonism in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 219-222.	1.5	44
135	Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 7-14.	2.2	44
136	Hyposmia in progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 570-577.	3.9	43
137	Visual sampling during walking in people with Parkinson's disease and the influence of environment and dual-task. <i>Brain Research</i> , 2012, 1473, 35-43.	2.2	42
138	Natural history of falls in an incident cohort of Parkinson's disease: early evolution, risk and protective features. <i>Journal of Neurology</i> , 2017, 264, 2268-2276.	3.6	42
139	Detecting Mild Cognitive Deficits in Parkinson's Disease: A Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	3.9	42
140	Cognition, coping, and outcome in Parkinson's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1656-1663.	1.0	41
141	Cognitive impairment in Parkinson's disease: impact on quality of life of carers. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1362-1370.	2.7	41
142	Gait Progression Over 6 Years in Parkinson's Disease: Effects of Age, Medication, and Pathology. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 577435.	3.4	41
143	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1280-1304.	2.7	39
144	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. <i>Brain Stimulation</i> , 2020, 13, 1031-1039.	1.6	39

#	ARTICLE	IF	CITATIONS
145	Mild depressive symptoms are associated with gait impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 634-639.	3.9	38
146	Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 452-455.	2.2	38
147	Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 139-141.	2.2	37
148	Primary sleep disorder prevalence in patients with newly diagnosed Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 259-262.	3.9	37
149	Impact of the <sc>COVID</sc>â€19 Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 357-360.	1.5	37
150	Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 776-782.	2.7	36
151	Is bed rest useful after diagnostic lumbar puncture?. <i>Postgraduate Medical Journal</i> , 1992, 68, 581-583.	1.8	35
152	Exome sequencing in dementia with Lewy bodies. <i>Translational Psychiatry</i> , 2016, 6, e728-e728.	4.8	35
153	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 509-516.	1.5	35
154	Longitudinal diffusion tensor imaging changes in early Parkinsonâ€™s disease: ICICLE-PD study. <i>Journal of Neurology</i> , 2018, 265, 1528-1539.	3.6	35
155	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. <i>Human Genetics</i> , 2008, 124, 95-99.	3.8	34
156	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinsonâ€™s Disease: The ICICLE-PD Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 193-206.	2.8	34
157	Prodromal Markers in Parkinsonâ€™s Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 147.	3.4	33
158	Cognition among individuals along a spectrum of increased risk for Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	2.5	33
159	No association between common <i>POLG1</i> variants and sporadic idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1092-1094.	3.9	32
160	Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. <i>Cortex</i> , 2017, 92, 8-18.	2.4	32
161	Risk of Parkinson's disease dementia related to level I MDS PDâ€™MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	3.9	32
162	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 668-675.	3.9	31

#	ARTICLE	IF	CITATIONS
163	Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <sc>DIAMOND</sc> Lewy study. International Journal of Geriatric Psychiatry, 2018, 33, 1293-1304.	2.7	31
164	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2019, 34, 1244-1250.	2.7	31
165	Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 351-359.	2.8	28
166	Synaptic Protein Alterations in Parkinson's Disease. Molecular Neurobiology, 2012, 45, 126-143.	4.0	27
167	Fluctuating cognition in the Lewy body dementias. Brain, 2019, 142, 3338-3350.	7.6	27
168	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26
169	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	2.8	25
170	Utility and accuracy of perceptual voice and speech distinctions in the diagnosis of Parkinson's disease, PSP and MSA-P. Neurodegenerative Disease Management, 2017, 7, 191-203.	2.2	25
171	Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Movement Disorders, 2021, 36, 611-621.	3.9	25
172	Coping in Parkinson's disease: an examination of the coping inventory for stressful situations. International Journal of Geriatric Psychiatry, 2011, 26, 1030-1037.	2.7	24
173	ProSaccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD. Movement Disorders, 2019, 34, 1690-1698.	3.9	24
174	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology, 2015, 45, 282-297.	2.3	23
175	The incidence of Parkinson's disease in the North-East of England. Age and Ageing, 2014, 43, 257-263.	1.6	22
176	Quality of Life and Mild Cognitive Impairment in Early Parkinson's Disease: Does Subtype Matter?. Journal of Parkinson's Disease, 2015, 4, 331-336.	2.8	22
177	Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2019, 64, 29-39.	2.2	22
178	Langerhans' cell histiocytosis and the nervous system. Journal of Neurology, 1992, 239, 345-350.	3.6	21
179	Tardive diaphragmatic flutter. Movement Disorders, 1998, 13, 190-192.	3.9	21
180	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	2.8	21

#	ARTICLE	IF	CITATIONS
181	Olfaction in <i>Parkin</i> single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 271-276.	2.1	21
182	Visual Hallucinations in Eye Disease and Lewy Body Disease. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 350-358.	1.2	21
183	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016, 25, 81-88.	3.1	20
184	Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson's Disease Cohort. <i>Journal of Parkinson's Disease</i> , 2017, 7, 465-470.	2.8	20
185	Strychnine poisoning as an unusual cause of convulsions. <i>Postgraduate Medical Journal</i> , 1989, 65, 563-564.	1.8	18
186	Parkinson's Disease Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 292-298.	4.2	18
187	Dorsal rather than ventral visual pathways discriminate freezing status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1094-1096.	2.2	18
188	Guided Self-Help for the Management of Worry in Parkinson's Disease: A Pilot Study. <i>Journal of Parkinson's Disease</i> , 2013, 3, 61-68.	2.8	18
189	Detecting new neurodegenerative disease genes: does phenotype accuracy limit the horizon?. <i>Trends in Genetics</i> , 2009, 25, 486-488.	6.7	17
190	The Treatment of Cognitive Impairment Associated with Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 672-678.	4.1	17
191	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2015, 5, 743-747.	2.8	17
192	The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). <i>Parkinsonism and Related Disorders</i> , 2000, 6, 145-153.	2.2	16
193	Motor Phenotypes, Medication and Mood: Further Associations with Impulsive Behaviours in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 245-254.	2.8	16
194	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 121.	3.4	16
195	Cognition in movement disorders: Where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014, 29, 704-711.	3.9	15
196	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 40-46.	2.2	15
197	Unacylated-Chrelin Impairs Hippocampal Neurogenesis and Memory in Mice and Is Altered in Parkinson's Dementia in Humans. <i>Cell Reports Medicine</i> , 2020, 1, 100120.	6.5	15
198	Amantadine-induced myoclonus in a patient with progressive supranuclear palsy. <i>Age and Ageing</i> , 2012, 41, 695-696.	1.6	14

#	ARTICLE	IF	CITATIONS
199	A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 329-332.	3.9	14
200	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 55-61.	2.2	14
201	Identifying delirium in Parkinson disease: A pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 547-552.	2.7	14
202	Muscarinic Receptors in the Thalamus in Progressive Supranuclear Palsy and Other Neurodegenerative Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 399-404.	1.7	13
203	Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 553-562.	4.7	13
204	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 49-53.	2.2	13
205	Mild cognitive impairment in Parkinson's disease: millstone or milestone?. <i>Practical Neurology</i> , 2013, 13, 68-69.	1.1	12
206	Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 765-770.	2.7	12
207	Levodopa use and sleep in patients with dementia with Lewy bodies. <i>Movement Disorders</i> , 2009, 24, 609-612.	3.9	11
208	Thyrotoxic Periodic Paralysis: Correct Hypokalemia with Caution. <i>Journal of Emergency Medicine</i> , 2013, 45, 338-340.	0.7	11
209	Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 594, 66-69.	2.1	11
210	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1297-1308.	2.8	11
211	Subthalamic deep brain stimulation in Parkinson's disease has no significant effect on perceptual timing in the hundreds of milliseconds range. <i>Neuropsychologia</i> , 2014, 57, 29-37.	1.6	10
212	Categorising Visual Hallucinations in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 447-453.	2.8	10
213	Altered network stability in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2021, 107, 109-117.	3.1	8
214	Hyperthyroid chorea. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 100, 279-286.	1.8	7
215	New horizons in the pathogenesis, assessment and management of movement disorders. <i>Age and Ageing</i> , 2013, 42, 2-10.	1.6	7
216	Patient and Informant Views on Visual Hallucinations in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 970-976.	1.2	7

#	ARTICLE	IF	CITATIONS
217	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	2.2	7
218	Semantic profiles in mild cognitive impairment associated with Alzheimer's and Parkinson's diseases. <i>Functional Neurology</i> , 2015, 30, 113-8.	1.3	7
219	Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias. <i>Journal of Chemical Neuroanatomy</i> , 2008, 35, 268-274.	2.1	6
220	Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 479, 123-125.	2.1	6
221	To sleep, perchance to dement: RBD and cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 671-673.	3.9	6
222	An Unusual Cause of Falls in a Young Woman. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2016, 46, 160-162.	0.6	6
223	Striatal dopaminergic loss without parkinsonism in a case of corticobasal degeneration. <i>Acta Neurologica Scandinavica</i> , 1997, 95, 287-292.	2.1	5
224	Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 511-515.	2.8	5
225	Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial. <i>Movement Disorders</i> , 2021, 36, 143-151.	3.9	5
226	Spatial Covariance of Cholinergic Muscarinic M_1 and M_4 Receptors in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1879-1888.	3.9	5
227	Clinical assessment of progressive supranuclear palsy over time: new rating scale validated. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 600-601.	2.5	4
228	Falling short: Underestimation of fracture risk in atypical parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 692-693.	2.2	4
229	Trajectories of pain over 6 years in early Parkinson's disease: ICICLE-PD. <i>Journal of Neurology</i> , 2021, 268, 4759-4767.	3.6	4
230	Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al. (<i>Brain</i> -2004-01045.R1). <i>Brain</i> , 2005, 128, 1235-1236.	7.6	3
231	Factors predicting discharge of Huntington's disease patients from a neuropsychiatry unit. <i>International Psychogeriatrics</i> , 2010, 22, 489-492.	1.0	3
232	Adult-onset myoclonus ataxia associated with the mitochondrial m.8993T>C> α -NARP mutation. <i>Movement Disorders</i> , 2015, 30, 1432-1433.	3.9	3
233	Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1923-1924.	3.9	3
234	UK Parkinson's Excellence Network: empowering service improvement across the UK. <i>Neurodegenerative Disease Management</i> , 2015, 5, 173-176.	2.2	2

#	ARTICLE	IF	CITATIONS
235	Dementia with Lewy bodies: The emerging role of primary care. <i>European Journal of General Practice</i> , 2016, 22, 53-57.	2.0	2
236	Two in the hand, an essential lesson in tremor management. <i>Practical Neurology</i> , 2010, 10, 160-163.	1.1	0
237	Commentary on the postencephalitic cases of Dr. Kinnier Wilson. <i>Movement Disorders</i> , 2011, 26, 2460-2461.	3.9	0
238	UK Parkinson's Excellence Network: time for a paradigm shift in Parkinson's care. <i>Neurodegenerative Disease Management</i> , 2015, 5, 177-180.	2.2	0
239	Embarking on a research project or research for the absolute novice. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2016, 46, 182-186.	0.6	0
240	Spectrum of Movement Disorders in Mitochondrial Disorders – Reply. <i>JAMA Neurology</i> , 2016, 73, 1254.	9.0	0
241	ABN News. <i>Practical Neurology</i> , 2017, 17, 84-84.	1.1	0